Imlygic: how was the first human dose set?

The public FDA and EMA reviews of Imlygic don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.

FDA expects preclinical proof-of-concept and toxicology studies to identify active dose levels and support the choice of starting dose and escalation. The 2013 guidance gives no numeric formula or scaling rule for the starting dose.

NOAEL / key findings: Single SC dose NOAEL 1e7 PFU/kg in mice (~1.7x max clinical dose); transient injection-site inflammation; HSV-1-related findings (FDA pharmacology/toxicology review, p. 99)

Full method, every step sourced →